Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002–2011

BMC Infectious Diseases

William R Bowie⁴  Masoud Yousefi²  Tim TY Lau³  Diane L Roscoe¹  Marcus von Krosigk³  Patrick HP Wong⁴ 

[1] Division of Medical Microbiology and Infection Control, Vancouver General Hospital (VGH), Vancouver, Canada;Brain Research Centre, UBC, Vancouver, Canada;Faculty of Pharmaceutical Sciences, UBC, Vancouver, Canada;Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, The University of British Columbia (UBC), 452D, Heather Pavilion East, VGH, 2733 Heather Street, Vancouver, BC V5Z 3J5, Canada

关键词: Antibiograms;    Bloodstream infections;    Gram-negative bacilli;    Multi-drug resistance;    Co-resistance;   

Others  :  1127180
DOI  :  10.1186/1471-2334-14-393

 received in 2014-03-17, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to public health. Few studies have analyzed co-resistance rates, defined as an antimicrobial susceptibility profile in a subset already resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance rates are analyzed and discussed.

Methods

A 10-year retrospective study from 2002–2011 of bloodstream infections with GNB were analyzed from three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns.

Results

The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual antimicrobials was observed for E. coli, K. pneumoniae, K. oxytoca, E. cloacae, and P. aeruginosa. Ciprofloxacin resistance in E. coli peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing ciprofloxacin usage after 2007, as assessed by defined daily dose utilization data. High co-resistance rates were observed for ceftriaxone-resistant E. coli with ciprofloxacin (73%), ceftriaxone-resistant K. pneumoniae with trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant E. cloacae with ticarcillin-clavulanate (91%), and piperacillin-tazobactam-resistant P. aeruginosa with ceftazidime (83%).

Conclusions

Increasing antimicrobial resistance was demonstrated over the study period, which may partially be associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides insight into the epidemiology of resistance acquisition, and may be used as a clinical tool to aid prescribing empiric antimicrobial therapy.

【 授权许可】

   
2014 Wong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kallen AJ, Srinivasan A: Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 2010, 31(Suppl 1):S51-54.
• [2]D'Agata EM: Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004, 25(10):842-846.
• [3]Gootz TD: The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance. Biochem Pharmacol 2006, 71(7):1073-1084.
• [4]Courvalin P, Trieu-Cuot P: Minimizing potential resistance: the molecular view. Clin Infect Dis 2001, 33(Suppl 3):S138-146.
• [5]Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert D: Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(Suppl 5):S397-428.
• [6]Pop-Vicas AE, D'Agata EM: The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005, 40(12):1792-1798.
• [7]McGowan JE Jr: Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006, 119(6 Suppl 1):S29-36. discussion S62-70
• [8]Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV: Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45(10):3352-3359.
• [9]Andrade SS, Jones RN, Gales AC, Sader HS: Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). J Antimicrob Chemother 2003, 52(1):140-141.
• [10]Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C: Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34(8):1047-1054.
• [11]Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A: Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004, 38(5):670-677.
• [12]Kriengkauykiat J, Porter E, Lomovskaya O, Wong-Beringer A: Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49(2):565-570.
• [13]CLSI: Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. [CLSI document M100-S20]
• [14]BC Centre for Disease Control: Antimicrobial Resistance Trends in the Province of British Columbia. 2012, 1-52. [http://www.bccdc.ca/util/about/annreport/default.htm#heading6 webcite]
• [15]Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52(5):e103-120.
• [16]Tan KE, Ellis BC, Lee R, Stamper PD, Zhang SX, Carroll KC: Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness. J Clin Microbiol 2012, 50(10):3301-3308.
• [17]Paterson DL: Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008, 47(Suppl 1):S14-20.